{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:09Z","timestamp":1791216729804,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.autrev.2023.103441","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T20:38:08Z","timestamp":1694551088000},"page":"103441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunoglobulins in systemic sclerosis management. A large multicenter experience"],"prefix":"10.1016","volume":"22","author":[{"given":"J.","family":"Tandaipan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guill\u00e9n-Del-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Sime\u00f3n-Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.E.","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De la Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Narv\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rubio-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Alegre-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Moriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Casafont-Sole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ortiz-Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Atienza-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Galisteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Pego-Reigosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Castellv\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.autrev.2023.103441_bb0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"10103","key":"10.1016\/j.autrev.2023.103441_bb0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.autrev.2023.103441_bb0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/BOR.0000000000000551","article-title":"Mortality and survival in systemic sclerosis: a review of recent literature","volume":"30","author":"Poudel","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000711","article-title":"Management of systemic sclerosis: the first five years","volume":"32","author":"Roofeh","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103441_bb0030","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103441_bb0035","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.autrev.2023.103441_bb0045","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.autrev.2023.103441_bb0050","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"10.1016\/j.autrev.2023.103441_bb0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000069447","article-title":"Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment","volume":"16","author":"Levy","year":"1998","journal-title":"Nat Immun"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jaci.2020.06.036","article-title":"Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fc\u03b3 receptors","volume":"146","author":"Shock","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103441_bb0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2567.2002.01545.x","article-title":"Immunomodulatory action of intravenous immunoglobulin","volume":"107","author":"Sewell","year":"2002","journal-title":"Immunology."},{"issue":"3s","key":"10.1016\/j.autrev.2023.103441_bb0075","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103441_bb0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jaci.2018.08.016","article-title":"Advances and highlights in primary immunodeficiencies in 2017","volume":"142","author":"Chinen","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0085","article-title":"Immunoglobulin for alloimmune hemolytic disease in neonates","volume":"3","author":"Zwiers","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2023.103441_bb0090","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jpeds.2018.07.065","article-title":"Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"204","author":"Lioger","year":"2019","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0095","doi-asserted-by":"crossref","first-page":"103019","DOI":"10.1016\/j.autrev.2021.103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","author":"Morales-Ruiz","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2023.103441_bb0100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0961203317696589","article-title":"Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus."},{"issue":"1","key":"10.1016\/j.autrev.2023.103441_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM study\u201d)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1385\/CRIAI:29:3:321","article-title":"Intravenous immunoglobulin and fibrosis","volume":"29","author":"Molina","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0120","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/art.10363","article-title":"The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice","volume":"46","author":"Blank","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0125","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","article-title":"A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion","volume":"44","author":"Asano","year":"2005","journal-title":"Rheumatology."},{"issue":"1","key":"10.1016\/j.autrev.2023.103441_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2012.09.010","article-title":"Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients","volume":"69","author":"Kudo","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103441_bb0140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2023.103441_bb0145","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2015","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103441_bb0150","doi-asserted-by":"crossref","first-page":"102981","DOI":"10.1016\/j.autrev.2021.102981","article-title":"Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from systematic literature review and from real life experience","volume":"20","author":"Agostini","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2023.103441_bb0155","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3109\/03009742.2013.868510","article-title":"Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis","volume":"43","author":"Mauhin","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103441_bb0160","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.1990.tb01462.x","article-title":"Efficacy of intravenous immunoglobulins in sclerodermatomyositis","volume":"123","author":"Bodemer","year":"1990","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103441_bb0165","first-page":"176","article-title":"Benefit of intravenous immunoglobulin in a patient with longstanding polymyositis\/systemic sclerosis overlap syndrome","volume":"40","author":"Abelha-Aleixo","year":"2015","journal-title":"Acta Reumatol Port"},{"issue":"4","key":"10.1016\/j.autrev.2023.103441_bb0170","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2023.103441_bb0175","doi-asserted-by":"crossref","first-page":"102431","DOI":"10.1016\/j.autrev.2019.102431","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients","volume":"19","author":"Chaigne","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"4 Suppl 91","key":"10.1016\/j.autrev.2023.103441_bb0180","first-page":"S168","article-title":"Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis","volume":"33","author":"Clark","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103441_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"19\u201320","key":"10.1016\/j.autrev.2023.103441_bb0190","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00508-020-01669-y","article-title":"Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis\u202f: single Centre experience","volume":"133","author":"Perkovi\u0107","year":"2021","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0195","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/crj.12281","article-title":"An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report","volume":"10","author":"Enomoto","year":"2016","journal-title":"Clin Respir J"},{"issue":"2 Suppl 76","key":"10.1016\/j.autrev.2023.103441_bb0200","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103441_bb0205","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0210","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0000000000000552","article-title":"Muscle disease in scleroderma","volume":"30","author":"Paik","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"SI","key":"10.1016\/j.autrev.2023.103441_bb0215","doi-asserted-by":"crossref","first-page":"SI82","DOI":"10.1093\/rheumatology\/keac361","article-title":"Clinico-pathological phenotypes of systemic sclerosis associated myopathy: analysis of a multicenter large cohort","volume":"62","author":"Matas-Garc\u00eda","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2023.103441_bb0220","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103441_bb0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/annrheumdis-2014-205295","article-title":"Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study","volume":"75","author":"Avouac","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"suppl_5","key":"10.1016\/j.autrev.2023.103441_bb0230","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kex196","article-title":"Muscle involvement in systemic sclerosis: points to consider in clinical trials","volume":"56","author":"Walker","year":"2017","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.autrev.2023.103441_bb0235","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103441_bb0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2397198319891282","article-title":"Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches","volume":"6","author":"Hoffmann-Vold","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"issue":"7","key":"10.1016\/j.autrev.2023.103441_bb0245","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103441_bb0250","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","article-title":"High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma","volume":"156","author":"Ihn","year":"2007","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103441_bb0255","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103441_bb0260","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archderm.144.5.585","article-title":"Response of dystrophic calcification to intravenous immunoglobulin","volume":"144","author":"Schanz","year":"2008","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103441_bb0265","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s12026-018-9047-y","article-title":"Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature","volume":"66","author":"Lidar","year":"2018","journal-title":"Immunol Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:30:09Z","timestamp":1761600609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1568997223001751"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103441","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulins in systemic sclerosis management. A large multicenter experience","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103441"}}